HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Training, financial considerations fuel debate about predict-resect-and-discard
-
- Immunotherapy trials shift breast cancer research closer to ‘Holy Grail’ Debu Tripathy, MD
- Several factors determine duration of anticoagulation for VTE Stephan Moll, MD
- 2014: What an interesting clinical year in GU oncology! Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Somatuline Depot for gastroenteropancreatic neuroendocrine tumors
- FDA approves 9-valent HPV vaccine for certain cancers
- FDA expands approval of ramucirumab to treat aggressive NSCLC
- FDA grants orphan drug status to JCAR015 for ALL treatment
- FDA allows marketing of neonatal SCID screening test
-
- FDA approves supplemental HTLV-I/II test
- FDA fast tracks necuparanib for metastatic pancreatic cancer
- R2CHOP appears highly active in DLBCL
- Discontinuation of eltrombopag deemed safe after complete remission of primary ITP
- FIRGEM regimen effective in metastatic pancreatic cancer
- Radical cystectomy, urinary diversion increased fracture risk among patients with bladder cancer
- ASCO issues policy statement targeting obesity–cancer link
- Lobectomy superior to sublobar resection for elderly patients with early-stage NSCLC
-
- Lung cancer screening would cost $81,000 per quality-adjusted life-year gained
- Postoperative chemoradiation improved survival in gastric cancer
- Sickle cell trait may increase risk for renal disease in blacks
- Survivors of osteosarcoma at increased risk for second malignant neoplasms
- Tumor characteristics influenced impact of adjuvant radiotherapy in prostate cancer
- Aspirin, COX-2 inhibitors improved outcomes in stage III colon cancer
- Bisphosphonates may hold potential for treatment, prevention of some cancers
- Combination of ibrutinib, rituximab induced responses in high-risk CLL
-
- Earlier initiation of adjuvant chemotherapy improved survival in rectal cancer
- Female survivors of Wilms tumor may be at increased risk for breast cancer
- Locally advanced unresectable disease, systemic treatment associated with longer OS in chondrosarcoma
- Longer course of first-line therapy provided no survival benefit in NSCLC
- Maintenance lenalidomide after alloHSCT improved response in high-risk multiple myeloma
- Melanoma tumor genetics determined clinical benefit from CTLA-4 blockades
- One-third of cancer patients experienced anxiety, mental health disorders
- Pioglitazone, rosiglitazone did not increase bladder cancer risk in patients with type 2 diabetes
-
- Sorafenib/RFA therapy improved OS, recurrence rates in HCC
- ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation
- Weekend admission increased hospital stays for children with leukemia
- Adjuvant regimen improved outcomes in gastric cancer after D2 gastrectomy
- Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease
- Breast cancer risk among childhood cancer survivors treated with radiation higher than previously thought
- Double-unit cord-blood transplant failed to extend survival in blood cancers
- Ipilimumab plus sargramostim prolonged OS, decreased toxicity in metastatic melanoma
-
- Addition of monoclonal antibody to reduced-intensity conditioning regimen effective in advanced B-cell lymphoma
- Fewer cardiac screenings may be appropriate for pediatric cancer survivors
- Advocacy group announces awards
- ASCO elects 2016 president
- Center makes staff announcements
- Clinician honored for breast cancer research
- Florida Atlantic University names VP of research
- Researcher on list of ‘most cited’
-
- Scientist named fellow of AAAS
- University appoints transplant director
- Azacitidine regimens failed to improve high-risk myelodysplastic syndromes
- VALOR: Vosaroxin improved survival in AML
- BLAST: Blinatumomab may effectively combat minimal residual disease in ALL
- Everolimus did not extend PFS in HER-2–positive breast cancer
- First-line fulvestrant extended OS in advanced, ER-positive breast cancer
- Pictilisib–fulvestrant combination doubled PFS in advanced ER-, PR-positive breast cancer
-
- Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT
- Multigene test predicted DCIS recurrence risk after breast-conserving surgery
- Majority of newborns with sickle cell disease survived to adulthood
- Nivolumab shows strong activity in classic Hodgkin’s lymphoma
- Reducing Factor XI may prevent postoperative thrombotic events
- Rituximab maintenance prolonged EFS, PFS in young patients with mantle cell lymphoma
- Sotatercept alleviated anemia burden in low-risk myelodysplastic syndrome
- Ultrasound improved cancer detection in women with dense breasts
-
- Extended anticoagulation reduced risk for recurrent VTE, major bleeding
- Lenalidomide targets CSNK1A1 in myelodysplastic syndrome with del(5q)
- Pediatric ALL regimen demonstrates solid results in AYA population
- Autologous HSCT evolves as standard of care for HIV-associated lymphoma
- Early thymic precursor immunophenotype does not affect T-cell ALL outcomes